- Home
- HCAT vs TVRD Comparison
HCAT vs TVRD Comparison
Compare HCAT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCAT
- TVRD
- Stock Information
- Founded
- HCAT 2008
- TVRD 2017
- Country
- HCAT United States
- TVRD United States
- Employees
- HCAT N/A
- TVRD N/A
- Industry
- HCAT Computer Software: Programming Data Processing
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- HCAT Technology
- TVRD Health Care
- Exchange
- HCAT Nasdaq
- TVRD Nasdaq
- Market Cap
- HCAT 259.8M
- TVRD 246.5M
- IPO Year
- HCAT 2019
- TVRD N/A
- Fundamental
- Price
- HCAT $3.68
- TVRD $25.69
- Analyst Decision
- HCAT Buy
- TVRD Strong Buy
- Analyst Count
- HCAT 11
- TVRD 5
- Target Price
- HCAT $8.00
- TVRD $59.20
- AVG Volume (30 Days)
- HCAT 452.0K
- TVRD 36.2K
- Earning Date
- HCAT 08-07-2025
- TVRD 08-21-2025
- Dividend Yield
- HCAT N/A
- TVRD N/A
- EPS Growth
- HCAT N/A
- TVRD N/A
- EPS
- HCAT N/A
- TVRD N/A
- Revenue
- HCAT $311,274,000.00
- TVRD N/A
- Revenue This Year
- HCAT $11.11
- TVRD N/A
- Revenue Next Year
- HCAT $9.27
- TVRD N/A
- P/E Ratio
- HCAT N/A
- TVRD N/A
- Revenue Growth
- HCAT 4.88
- TVRD N/A
- 52 Week Low
- HCAT $3.49
- TVRD $8.13
- 52 Week High
- HCAT $9.24
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- HCAT 43.17
- TVRD N/A
- Support Level
- HCAT $3.79
- TVRD N/A
- Resistance Level
- HCAT $4.12
- TVRD N/A
- Average True Range (ATR)
- HCAT 0.18
- TVRD 0.00
- MACD
- HCAT -0.00
- TVRD 0.00
- Stochastic Oscillator
- HCAT 13.86
- TVRD 0.00
About HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.